Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy.

TitleDevelopment and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy.
Publication TypeJournal Article
Year of Publication2016
AuthorsPatri P, Seshan SV, Matignon M, Desvaux D, Lee JR, Lee J, Dadhania DM, Serur D, Grimbert P, Hartono C, Muthukumar T
JournalKidney Int
Volume89
Issue2
Pagination450-8
Date Published2016 Feb
ISSN1523-1755
KeywordsAdult, Female, Graft Survival, Humans, Kidney Diseases, Kidney Transplantation, Male, Middle Aged, Postoperative Complications, Severity of Illness Index
Abstract

We studied 92 patients with transplant glomerulopathy to develop a prognostic index based on the risk factors for allograft failure within five years of diagnosis (Development cohort). During 60 months (median) follow-up, 64 patients developed allograft failure. A chronic-inflammation score generated by combining Banff ci, ct and ti scores, serum creatinine and proteinuria at biopsy, were independent risk factors for allograft failure. Based on the Cox model, we developed a prognostic index and classified patients into risk groups. Compared to the low-risk group (median allograft survival over 60 months from diagnosis), patients in the medium risk group had a hazard ratio of 2.83 (median survival 25 months), while those in the high-risk group had a hazard ratio of 5.96 (median survival 3.7 months). We next evaluated the performance of the prognostic index in an independent external cohort of 47 patients with transplant glomerulopathy (Validation cohort). The hazard ratios were 2.18 (median survival 19 months) and 16.27 (median survival 1.6 months), respectively, for patients in the medium and high-risk groups, compared to the low-risk group (median survival 47 months). Our prognostic index model did well in measures of discrimination and calibration. Thus, risk stratification of transplant glomerulopathy based on our prognostic index may provide informative insight for both the patient and physician regarding prognosis and treatment.

DOI10.1038/ki.2015.288
Alternate JournalKidney Int
PubMed ID26422505
PubMed Central IDPMC4814368
Grant ListK08 DK087824 / DK / NIDDK NIH HHS / United States
UL1 TR000457 / TR / NCATS NIH HHS / United States
K08-DK087824 / DK / NIDDK NIH HHS / United States
UL1TR000457 / TR / NCATS NIH HHS / United States
Related Faculty: 
Surya V. Seshan, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700